Clinical Trial

Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2025 (before its estimated July 5, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is designed to evaluate the safety, tolerability, PK and PD of multiple subcutaneous injections of GenSci120 in a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase Ib trial involving healthy adult participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-18; most recent amendment 2025-08-05.
Status change: Not Yet Recruiting → Recruiting 2025-08-05
Trial Details
NCT Number NCT07040930
Lead Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions Rheumatoid Arthritis
Enrollment 30 participants
Start Date 2025-08-01
Primary Completion 2026-07-05 (estimated)
Study Completion 2026-09-20 (estimated)
Updated on ClinicalTrials.gov 2025-08-06